Assembly the worldwide demand for cell therapies: scaling with sensible manufacturing

Cell therapies are on the slicing fringe of customized medication however as demand for these therapies grows, how will the business scale manufacturing to fulfill affected person wants?

Fabian Gerlinghaus is co-founder and CEO of Cellares. He and his crew have developed the Cell Shuttle, a sophisticated cell manufacturing expertise that’s already demonstrating the potential to 10x cell yields whereas halving prices for prescribed drugs corporations and innovators. Is that this the long run for sensible cell manufacturing?

0:52     A place to begin in aeronautical engineering

2:43     First steps into biotech

5:25     Co-founding Cellares

6:30     The issue that Cellares addresses

11:02   Greatest follow bio manufacturing

17:14   Differentiation in automation

18:15   What does success seem like for Cellares

19:38   Sensible factories

21:58   Contained in the Cellares sensible manufacturing unit

26:34   Manufacturing CAR-T and stem cell therapies

27:54   Mass manufacturing vs customized medication

31:39   International ambitions and regional regulators

35:07   Positioning Cellares out there

Inquisitive about being a sponsor of an episode of our podcast? Uncover how one can get entangled right here! 

Keep up to date by subscribing to our e-newsletter